Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification.
J Neurooncol
2026
177
2
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.
Lancet Oncol
2026
27
4
480-490
From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials.
J Nucl Med
2026
67
1
19-22
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
2026
67
1
92-95
Reply to "AI Disclosure Policies: Are We Rearranging Deck Chairs on the Titanic?".
J Nucl Med
2026
67
5
827-828
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.
J Nucl Med
2026
Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.
J Nucl Med
2026
67
7
1093-1096
Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy.
Eur J Nucl Med Mol Imaging
2026
53
9
5417-5426
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus].
Urologie
2026
65
5
480-489